Actualités 17 Abr 2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
News 10 Ene 2024 The remarkable chemical-pharmaceutical industry in the canton of Valais For decades, the canton of Valais has cultivated a reputation for excellence in the chemical and pharmaceutical industries, combining innovation ...
News 17 Abr 2024 Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug develop...
Actualités 14 Ago 2023 L’écosystème florissant de Berne pour l’innovation en sciences de la vie Au cœur de la Suisse occidentale, le canton de Berne s'est imposé comme une destination de choix pour les entreprises du secteur des sciences de ...
Aktuell 18 Oct 2022 KetoSwiss erhöht Kapital um 4 Millionen Dollar KetoSwiss hat von Investoren 4 Millionen Dollar erhalten. Das Basler Start-up entwickelt Produkte zur Linderung neurologischer Erkankungen wie Mi...
News 29 Sep 2023 Top Stories from Western Switzerland (July-September 2023) From spearheading eco-innovative solutions to pioneering breakthroughs in solar technology, cancer research, sustainable shipping, and the realms...
News 14 Ago 2023 Bern’s thriving ecosystem for life sciences innovation In the heart of Western Switzerland, the canton of Bern has emerged as a location of choice for companies in the life sciences sector.
News 18 Oct 2022 KetoSwiss secures capital increase of 4 million dollars KetoSwiss has banked a total of 4 million US dollars from investors. The Basel-based start-up develops products to alleviate neurological disease...
News 01 Feb 2022 Merck acquires Geneva-based biopharmaceutical company Chord Therapeutics Chord Therapeutics, a clinical stage biopharmaceutical company developing drugs for rare neuroinflammatory diseases, is being acquired by Merck.
News 29 Ene 2024 Biomanufacturing innovator Stämm opens its European R&D facility in Monthey Stämm, an innovative leader in bioprocessing technology, has announced the opening of its new R&D facility at the BioArk in Monthey, in the canto...
News 23 Oct 2023 Valsynthèse, 40 years of innovation in the canton of Valais From dynamite to pharmaceuticals, Valsynthèse, the 'fine chemistry' business unit of the Société Suisse des Explosifs, celebrates four decades of...
News 25 Oct 2023 Mecaplast Swiss, 50 years of innovation in the canton of Fribourg With a rich history spanning five decades, Mecaplast Swiss has consistently proven itself as a leader in the plastic injection industry, particul...
News 01 Nov 2023 Bacthera’s Visp plant aims to revolutionize microbiome-based treatments In Visp, Bacthera’s MC4a Center of Excellence readies to manufacture transformative microbiome therapies, notably the Seres Therapteutics’ life-s...
News 16 Jun 2023 Saiba Animal Health issues license to Boehringer Ingelheim German pharmaceutical company Boehringer Ingelheim has secured an exclusive license for a Saiba Animal Health product candidate. This is the seco...
Analyse 22 Mar 2021 Digitales B2B-Marketing in China Die digitale Landschaft in China ist einzigartig und in rasanter Entwicklung, ganz anders als in Europa. Um herauszufinden, wo Schweizer Unterneh...
Analyse 22 Mar 2021 Marketing digital B2B en Chine En constante évolution, le paysage du numérique chinois est unique en son genre et radicalement différent de son équivalent européen. Afin de sav...
News 01 Feb 2023 SSE Group and Hypex Bio join forces for an environmentally friendly explosive solution The Société Suisse des Explosifs (SSE) has entered into a partnership with Swedish company Hypex Bio Explosives Technology to market its new envi...